We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
RNA category is based on mRNA expression levels in the analyzed samples (RNA assay description). The categories include: tissue/cell line enriched, group enriched, tissue/cell line enhanced, expressed in all, mixed and not detected. RNA category is calculated separately for The Cancer Genome Atlas (TCGA) data from cancer tissues and internally generated Human Protein Atlas (HPA) data from normal tissues and cell lines.
TCGA (cancer tissue):
Expressed in all
HPA (cell line):
Expressed in all
HPA (normal tissue):
Expressed in all
Protein evidencei
Protein evidence scores are generated from several independent sources and are classified as evidence at i) protein level, ii) transcript level, iii) no evidence, or iv) not available.
Evidence at protein level
IMMUNOHISTOCHEMISTRY DATA RELIABILITY
Reliability score - normal tissuesi
Reliability score (score description), divided into Enhanced, Supported, Approved, or Uncertain, is evaluated in normal tissues and based on consistency between antibody staining pattern, available RNA-Seq and gene/protein characterization data, as well as similarity between independent antibodies targeting the same protein.
Kaplan-Meier plots for all cancers where high expression of this gene has significant (p<0.001) association with patient survival are shown in this summary. Whether the prognosis is favourable or unfavourable is indicated in brackets. Each Kaplan-Meier plot is clickable and redirects to a detailed page that includes individual expression and survival data for patients with the selected cancer.
RNA expression overview shows RNA-seq data from The Cancer Genome Atlas (TCGA).
TCGA dataseti
RNA-seq data in 17 cancer types are reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA). RNA cancer tissue category is calculated based on mRNA expression levels across all 17 cancer tissues and include: cancer tissue enriched, cancer group enriched, cancer tissue enhanced, expressed in all, mixed and not detected. To access cancer specific RNA and prognostic data, click on the cancer name. The cancer types are color-coded according to which type of normal organ the cancer originates from.
Antibody staining in 20 different cancers is summarized by a selection of four standard cancer tissue samples representative of the overall staining pattern. From left: colorectal cancer, breast cancer, prostate cancer and lung cancer. An additional fifth image can be added as a complement. The assay and annotation is described here. Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.
Gene information from Ensembl and Entrez, as well as links to available gene identifiers are displayed here. Information was retrieved from Ensembl if not indicated otherwise.
Gene name
PPP2R1A (HGNC Symbol)
Synonyms
PP2A-Aalpha, PP2AA, PR65A
Description
Protein phosphatase 2 scaffold subunit Aalpha (HGNC Symbol)
Entrez gene summary
This gene encodes a constant regulatory subunit of protein phosphatase 2. Protein phosphatase 2 is one of the four major Ser/Thr phosphatases, and it is implicated in the negative control of cell growth and division. It consists of a common heteromeric core enzyme, which is composed of a catalytic subunit and a constant regulatory subunit, that associates with a variety of regulatory subunits. The constant regulatory subunit A serves as a scaffolding molecule to coordinate the assembly of the catalytic subunit and a variable regulatory B subunit. This gene encodes an alpha isoform of the constant regulatory subunit A. Alternatively spliced transcript variants have been described. [provided by RefSeq, Apr 2010]
The protein browser displays the antigen location on the target protein(s) and the features of the target protein. The tabs at the top of the protein view section can be used to switch between the different splice variants to which an antigen has been mapped.
At the top of the view, the position of the antigen (identified by the corresponding HPA identifier) is shown as a green bar. A yellow triangle on the bar indicates a <100% sequence identity to the protein target.
Under the antigens, the maximum percent sequence identity of the protein to all other proteins from other human genes is displayed, using a sliding window of 10 aa residues (HsID 10) or 50 aa residues (HsID 50). The region with the lowest possible identity is always selected for antigen design, with a maximum identity of 60% allowed for designing a single-target antigen (read more).
The curve in blue displays the predicted antigenicity i.e. the tendency for different regions of the protein to generate an immune response, with peak regions being predicted to be more antigenic.The curve shows average values based on a sliding window approach using an in-house propensity scale. (read more).
If a signal peptide is predicted by a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius (turquoise) and/or transmembrane regions (orange) are predicted by MDM, these are displayed.
Low complexity regions are shown in yellow and InterPro regions in green. Common (purple) and unique (grey) regions between different splice variants of the gene are also displayed (read more), and at the bottom of the protein view is the protein scale.
PPP2R1A-001
PPP2R1A-003
PPP2R1A-004
PPP2R1A-005
PPP2R1A-012
PPP2R1A-201
PROTEIN INFORMATIONi
The protein information section displays alternative protein-coding transcripts (splice variants) encoded by this gene according to the Ensembl database.
The ENSP identifier links to the Ensembl website protein summary, while the ENST identifier links to the Ensembl website transcript summary for the selected splice variant. The data in the UniProt column can be expanded to show links to all matching UniProt identifiers for this protein.
The protein classes assigned to this protein are shown if expanding the data in the protein class column. Parent protein classes are in bold font and subclasses are listed under the parent class.
The Gene Ontology terms assigned to this protein are listed if expanding the Gene ontology column. The length of the protein (amino acid residues according to Ensembl), molecular mass (kDalton), predicted signal peptide (according to a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius) and the number of predicted transmembrane region(s) (according to MDM) are also reported.
P30153 [Direct mapping] Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform A8K7B7 [Target identity:100%; Query identity:100%] Protein phosphatase 2 (Formerly 2A), regulatory subunit A (PR 65), alpha isoform; Testicular secretory protein Li 1; cDNA FLJ78455, highly similar to Homo sapiens protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), alpha isoform (PPP2R1A), mRNA; cDNA, FLJ96799, Homo sapiens protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), alpha isoform (PPP2R1A), mRNA
Show all
Predicted intracellular proteins Plasma proteins Cancer-related genes Mutated cancer genes Mutational cancer driver genes COSMIC somatic mutations in cancer genes COSMIC Somatic Mutations COSMIC Missense Mutations Disease related genes Protein evidence (Kim et al 2014) Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000086 [G2/M transition of mitotic cell cycle] GO:0000159 [protein phosphatase type 2A complex] GO:0000184 [nuclear-transcribed mRNA catabolic process, nonsense-mediated decay] GO:0000188 [inactivation of MAPK activity] GO:0000775 [chromosome, centromeric region] GO:0003823 [antigen binding] GO:0004722 [protein serine/threonine phosphatase activity] GO:0005515 [protein binding] GO:0005634 [nucleus] GO:0005694 [chromosome] GO:0005737 [cytoplasm] GO:0005739 [mitochondrion] GO:0005829 [cytosol] GO:0006275 [regulation of DNA replication] GO:0006355 [regulation of transcription, DNA-templated] GO:0006461 [protein complex assembly] GO:0006470 [protein dephosphorylation] GO:0006672 [ceramide metabolic process] GO:0006915 [apoptotic process] GO:0007059 [chromosome segregation] GO:0007084 [mitotic nuclear envelope reassembly] GO:0007143 [female meiotic division] GO:0008380 [RNA splicing] GO:0010033 [response to organic substance] GO:0015630 [microtubule cytoskeleton] GO:0016020 [membrane] GO:0019888 [protein phosphatase regulator activity] GO:0019932 [second-messenger-mediated signaling] GO:0030111 [regulation of Wnt signaling pathway] GO:0030155 [regulation of cell adhesion] GO:0030308 [negative regulation of cell growth] GO:0040008 [regulation of growth] GO:0042518 [negative regulation of tyrosine phosphorylation of Stat3 protein] GO:0045595 [regulation of cell differentiation] GO:0046982 [protein heterodimerization activity] GO:0050790 [regulation of catalytic activity] GO:0051232 [meiotic spindle elongation] GO:0051306 [mitotic sister chromatid separation] GO:0051754 [meiotic sister chromatid cohesion, centromeric] GO:0070062 [extracellular exosome] GO:0070262 [peptidyl-serine dephosphorylation] GO:0097711 [ciliary basal body docking] GO:1903538 [regulation of meiotic cell cycle process involved in oocyte maturation] GO:2001241 [positive regulation of extrinsic apoptotic signaling pathway in absence of ligand]
B3KQV6 [Direct mapping] Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform; cDNA FLJ33169 fis, clone ADRGL2000384, highly similar to Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform
Show all
Predicted intracellular proteins Cancer-related genes Mutated cancer genes Mutational cancer driver genes COSMIC somatic mutations in cancer genes COSMIC Somatic Mutations COSMIC Missense Mutations Protein evidence (Ezkurdia et al 2014)
SPOCTOPUS predicted secreted proteins Predicted intracellular proteins Cancer-related genes Mutated cancer genes Mutational cancer driver genes COSMIC somatic mutations in cancer genes COSMIC Somatic Mutations COSMIC Missense Mutations Protein evidence (Ezkurdia et al 2014)
Predicted intracellular proteins Cancer-related genes Mutated cancer genes Mutational cancer driver genes COSMIC somatic mutations in cancer genes COSMIC Somatic Mutations COSMIC Missense Mutations Protein evidence (Ezkurdia et al 2014)
Predicted intracellular proteins Cancer-related genes Mutated cancer genes Mutational cancer driver genes COSMIC somatic mutations in cancer genes COSMIC Somatic Mutations COSMIC Missense Mutations Protein evidence (Ezkurdia et al 2014)
The Human Protein Atlas project is funded
MENU
